pmid	doi	year	title	Hugo_Symbol
34310368	10.1097/PAS.0000000000001785	2022	Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas.	IRF4
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	IRF4
34622970	10.1111/cup.14147	2022	Primary cutaneous anaplastic large-cell lymphoma with DUSP22-IRF4 rearrangement following insect bites.	IRF4
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	IRF4
34699105	10.1111/cup.14156	2022	Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas.	IRF4
34705295	10.1111/cup.14157	2022	Primary cutaneous anaplastic large-cell lymphoma with aberrant cytokeratin expression: An unusual mimicker of poorly differentiated carcinomas.	IRF4
34775495	10.1038/s41374-021-00638-x	2022	microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis.	IRF4
34791573	10.1007/s10014-021-00415-0	2022	Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.	IRF4
34801601	10.1016/j.humpath.2021.11.007	2022	Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma.	IRF4
34913532	10.1002/pro.4260	2022	The molecular basis for the development of adult T-cell leukemia/lymphoma in patients with an IRF4<sup>K59R</sup> mutation.	IRF4
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	IRF4
34962700	10.1002/pbc.29527	2022	Importance of clinical correlation in the diagnosis of pediatric B-cell lymphomas.	IRF4
35001425	10.1111/cup.14199	2022	Primary cutaneous CD8+ cytotoxic T-cell lymphoma of the face with intraoral involvement, resulting in facial nerve palsy after chemotherapy.	IRF4
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	IRF4
35142151	10.3324/haematol.2021.279908	2022	A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.	IRF4
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	IRF4
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	IRF4
35338347	10.1038/s41417-022-00450-9	2022	SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.	IRF4
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	IRF4
35472072	10.1371/journal.ppat.1010453	2022	Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.	IRF4
35504924	10.1038/s41467-022-30053-9	2022	IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.	IRF4
35560037	10.1111/1346-8138.16424	2022	Primary cutaneous anaplastic large cell lymphoma with DUSP22-IRF4 rearrangement demonstrating a biphasic histopathologic pattern and a complete natural regression.	IRF4
35675522	10.1182/bloodadvances.2022007725	2022	ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.	IRF4
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	IRF4
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	IRF4
35884913	10.3390/biomedicines10071608	2022	Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.	IRF4
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	IRF4
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	IRF4
35983077	10.1155/2022/9544827	2022	Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.	IRF4
35984488	10.1007/s00428-022-03385-6	2022	Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.	IRF4
36009586	10.3390/biomedicines10082038	2022	Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma.	IRF4
36047964	10.1111/cas.15550	2022	Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.	IRF4
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	IRF4
32749698	10.1002/jcp.29953	2021	Roles of BATF/JUN/IRF4 complex in tacrolimus mediated immunosuppression on Tfh cells in acute rejection after liver transplantation.	IRF4
33150420	10.1182/blood.2020005083	2021	Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.	IRF4
33406405	10.1016/j.cmet.2020.12.011	2021	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma.	IRF4
33411730	10.1371/journal.ppat.1009091	2021	Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.	IRF4
33503299	10.1111/pin.13067	2021	B cell lymphoma with IRF4 rearrangement: A clinicopathological study of 13 cases.	IRF4
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	IRF4
33597573	10.1038/s41598-021-83352-4	2021	Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.	IRF4
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	IRF4
33654205	10.1038/s41375-021-01181-w	2021	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.	IRF4
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	IRF4
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	IRF4
34078047	10.3760/cma.j.cn112151-20210204-00127	2021	[Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].	IRF4
34164830	10.1111/cup.14089	2021	Primary cutaneous anaplastic large-cell lymphoma with 6p25.3 rearrangement exhibits a biphasic histopathologic pattern: Two case reports and literature review.	IRF4
34304770	10.1016/j.cll.2021.03.018	2021	Update on Pediatric and Young Adult Mature Lymphomas.	IRF4
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	IRF4
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	IRF4
34477080		2021	Indurated Plaques on the Legs: Think Lymphoma.	IRF4
34484219	10.3389/fimmu.2021.716240	2021	Coupled Antigen and BLIMP1 Asymmetric Division With a Large Segregation Between Daughter Cells Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells and a DZ-to-LZ Ratio in the Germinal Center.	IRF4
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	IRF4
34944796	10.3390/cancers13246174	2021	RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulation of PI3K/AKT Signaling via Neurotrophin Pathway Genes.	IRF4
31324665	10.1136/jclinpath-2019-205915	2020	Tonsillar follicular large B-cell lymphoma with <i>IRF4</i> rearrangement causing sleep apnoea.	IRF4
31361906	10.1111/his.13964	2020	Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.	IRF4
31631721	10.1177/1066896919883013	2020	Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes.	IRF4
31688142	10.1097/PAS.0000000000001399	2020	Unusual Variants of Follicular Lymphoma: Case-based Review.	IRF4
31725418	10.1097/PAP.0000000000000253	2020	Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.	IRF4
31735345	10.1016/j.pathol.2019.08.013	2020	Diffuse large B-cell lymphoma variants: an update.	IRF4
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	IRF4
31773249	10.1007/s00428-019-02704-8	2020	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.	IRF4
31882178	10.1053/j.semdp.2019.12.002	2020	Pathology and genetics of anaplastic large cell lymphoma.	IRF4
31914056	10.1097/MD.0000000000018670	2020	Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma.	IRF4
31964683	10.1136/jclinpath-2019-206267	2020	Application of 2016 WHO classification in the diagnosis of paediatric high-grade <i>MYC</i>-negative mature B-cell lymphoma with Burkitt-like morphological features.	IRF4
31972002	10.1182/blood.2019002639	2020	Feed-forward regulatory loop driven by IRF4 and NF-ÎºB in adult T-cell leukemia/lymphoma.	IRF4
32100965	10.1111/ddg.14041	2020	Lymphomatoid papulosis.	IRF4
32202225	10.1177/0300985820913265	2020	Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.	IRF4
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	IRF4
32239695	10.1111/bjh.16578	2020	Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.	IRF4
32349466	10.4274/tjh.galenos.2020.2020.0086	2020	<i>IRF4</i>-Rearranged Large B-Cell Lymphoma on Waldeyerâs Ring: A Case Report	IRF4
32585984	10.3390/cancers12061669	2020	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma.	IRF4
32610392	10.3760/cma.j.cn112151-20200213-00089	2020	[Large B-cell lymphoma with atypical IRF4 rearrangement: report of a case].	IRF4
32753663	10.1038/s41598-020-69884-1	2020	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.	IRF4
32761226	10.1182/blood.2020006406	2020	Early pattern of large B-cell lymphoma with IRF4 rearrangement.	IRF4
32771332	10.1016/j.oraloncology.2020.104910	2020	Primary intraosseous CD9-positive B-cell lymphoblastic lymphoma of the maxilla affecting a pediatric patient: Immunohistochemical and in situ hybridization analysis.	IRF4
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	IRF4
32817485	10.1073/pnas.1922216117	2020	Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional <i>MYC</i> superenhancers and enhancer RNAs.	IRF4
32843547	10.1128/mBio.01457-20	2020	Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.	IRF4
32859220	10.1186/s12977-020-00535-z	2020	Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.	IRF4
32889849	10.1097/QAD.0000000000002590	2020	HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.	IRF4
32909092	10.1007/s00292-020-00816-6	2020	[Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].	IRF4
32914098	10.1158/2643-3230.BCD-20-0009	2020	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma.	IRF4
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	IRF4
32922661	10.18632/oncotarget.27683	2020	The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL).	IRF4
32992413	10.3760/cma.j.cn112151-20200601-00433	2020	[Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement].	IRF4
33017467	10.1182/bloodadvances.2020002049	2020	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.	IRF4
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	IRF4
33357426	10.1016/j.celrep.2020.108517	2020	Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4.	IRF4
33613551	10.3389/fimmu.2020.620716	2020	Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.	IRF4
29718735	10.1080/10428194.2018.1466290	2019	Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.	IRF4
30016448	10.1093/labmed/lmy035	2019	Anaplastic Large Cell Lymphoma Manifesting as Pleural Effusion in a Patient with Long-Standing Eosinophilia.	IRF4
30019203	10.1007/s00292-018-0456-4	2019	[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]	IRF4
30068263	10.1080/10428194.2018.1485915	2019	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.	IRF4
30277089	10.1080/10428194.2018.1508669	2019	A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).	IRF4
30380402	10.1016/j.anndiagpath.2018.09.014	2019	Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.	IRF4
30457169	10.1111/his.13794	2019	Biphasic pathological pattern in transformed mycosis fungoides not associated with DUSP22-IRF4 translocation.	IRF4
30664244	10.1002/eji.201847855	2019	Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.	IRF4
30695866	10.3760/cma.j.issn.0529-5807.2019.02.011	2019	[Clinicopathological features of follicular lymphoma in children].	IRF4
30732171	10.1097/MD.0000000000014367	2019	Diffuse large B-cell lymphoma of the central nervous system presenting as ""lymphomatosis cerebri"" and dementia in elderly man: Case report and review of the literature.	IRF4
30792929	10.1155/2019/3730915	2019	CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.	IRF4
30802809	10.1016/j.anndiagpath.2019.02.001	2019	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.	IRF4
30907723	10.1099/jgv.0.001249	2019	IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.	IRF4
30962205	10.1182/blood.2018880138	2019	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.	IRF4
31012208	10.1002/pbc.27770	2019	IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.	IRF4
31039827	10.1186/s13073-019-0637-7	2019	A modular transcriptome map of mature B cell lymphomas.	IRF4
31101622	10.1182/blood.2019000626	2019	Recurrent <i>MSC</i> <sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphoma.	IRF4
31102405	10.1093/neuonc/noz088	2019	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.	IRF4
31104675	10.3760/cma.j.issn.0529-5807.2019.05.006	2019	[Clinicopathological features and molecular genetics of paediatric-type follicular lymphoma: report of eight cases].	IRF4
31151983	10.1182/blood.2019001043	2019	A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.	IRF4
31187530	10.1002/hon.2585	2019	Rare mature B-cell lymphomas in children and adolescents.	IRF4
31278738	10.1093/ajcp/aqz078	2019	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms.	IRF4
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	IRF4
31331250	10.2217/pme-2018-0068	2019	Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.	IRF4
31363108	10.1038/s41598-019-47343-w	2019	A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line.	IRF4
31570354	10.1136/bcr-2019-230641	2019	<i>DUSP22-IRF4</i> rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.	IRF4
31584842	10.5858/arpa.2019-0331-RA	2019	Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.	IRF4
31594013	10.1055/a-0597-7606	2019	[Current standard in diagnostic and therapy of peripheral T-cell lymphoma].	IRF4
31837029	10.1111/vcp.12816	2019	Lymphoma with Mott cell differentiation and validation of immunohistochemical lymphoid markers in an African pygmy hedgehog (Atelerix albiventris).	IRF4
29084771	10.1182/blood-2017-01-761874	2018	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.	IRF4
29097500	10.3324/haematol.2017.179309	2018	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.	IRF4
29122756	10.1182/blood-2017-08-799080	2018	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.	IRF4
29154209	10.1016/j.molimm.2017.11.011	2018	External signals regulate germinal center fate-determining transcription factors in the A20 lymphoma cell line.	IRF4
29251015	10.1080/10428194.2017.1410884	2018	Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.	IRF4
29253230	10.3382/ps/pex343	2018	Correlation between miRNAs and target genes in response to Campylobacter jejuni inoculation in chicken.	IRF4
29346274	10.3390/cancers10010021	2018	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.	IRF4
29397940	10.1016/j.bbrc.2018.01.154	2018	KSHV vIRF4 enhances BCL6 transcription via downregulation of IRF4 expression.	IRF4
29467311	10.1128/JVI.02155-17	2018	Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.	IRF4
29540473	10.1074/jbc.RA117.000164	2018	An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.	IRF4
29555645	10.1182/blood-2018-01-824540	2018	Epigenetic silencing of miR-125b is required for normal B-cell development.	IRF4
29567771	10.3324/haematol.2017.181024	2018	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.	IRF4
29588546	10.1038/s41375-018-0045-9	2018	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.	IRF4
29616088	10.3892/ol.2018.8014	2018	Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model.	IRF4
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	IRF4
29676376	10.4103/IJPM.IJPM_194_17	2018	An unusual presentation of large B-cell lymphoma with interferon regulatory factor 4 gene rearrangement.	IRF4
29684346	10.1016/j.bbrc.2018.04.159	2018	MicroRNA-3662 expression correlates with antiviral drug resistance in adult T-cell leukemia/lymphoma cells.	IRF4
29738359	10.1097/PAS.0000000000001071	2018	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.	IRF4
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	IRF4
29954751	10.1182/blood-2018-01-828418	2018	CK1Î± and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.	IRF4
29992063	10.1155/2018/5320590	2018	A Rare Case of ALK-Positive Large B-Cell Lymphoma with CD33 Expression.	IRF4
29992138	10.1155/2018/3574534	2018	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.	IRF4
30021904	10.1128/JVI.00716-18	2018	Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.	IRF4
30032036	10.1016/j.neo.2018.07.001	2018	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.	IRF4
30057145	10.1016/j.ccell.2018.06.014	2018	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.	IRF4
30111411	10.7534/j.issn.1009-2137.2018.04.023	2018	[Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].	IRF4
30111820	10.1038/s41467-018-05506-9	2018	Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.	IRF4
30125329	10.1371/journal.ppat.1007221	2018	An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.	IRF4
30207048	10.1002/pbc.27399	2018	Burkitt lymphoma in Iraqi children: A distinctive form of sporadic disease with high incidence of EBV<sup>+</sup> cases and more frequent expression of MUM1/IRF4 protein in cases with head and neck presentation.	IRF4
30305518	10.11406/rinketsu.59.2127	2018	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	IRF4
30305637	10.1038/s41467-018-06541-2	2018	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia.	IRF4
30348505	10.1016/j.pathol.2018.08.008	2018	Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression.	IRF4
30522172	10.3760/cma.j.issn.0529-5807.2018.12.005	2018	[Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].	IRF4
30701929	10.26442/terarkh201890796-101	2018	Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature.	IRF4
31360094	10.2147/BLCTT.S142814	2018	Plasmablastic lymphoma: current perspectives.	IRF4
27616053	10.1002/pbc.26236	2017	IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10.	IRF4
28079574	10.1097/PAS.0000000000000804	2017	Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan.	IRF4
28263097	10.1080/08916934.2017.1284821	2017	Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.	IRF4
28357165	10.7759/cureus.1033	2017	Persistent Afebrile Abdominal Pain: An Unusual Case of Segmental Colitis in an Immunocompromised Host.	IRF4
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	IRF4
28368411	10.1038/onc.2017.79	2017	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.	IRF4
28369050	10.1038/ni.3716	2017	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.	IRF4
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	IRF4
28494239	10.1016/j.chom.2017.04.005	2017	CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.	IRF4
28529614	10.7150/jca.17358	2017	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.	IRF4
28600336	10.1182/blood-2017-02-734541	2017	Diagnosis and classification of hematologic malignancies on the basis of genetics.	IRF4
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	IRF4
28693749	10.1016/j.pathol.2017.05.007	2017	Primary gastrointestinal anaplastic large cell lymphoma.	IRF4
28910419	10.1371/journal.ppat.1006597	2017	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.	IRF4
29056123	2721	2017	Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.	IRF4
29070116	10.7534/j.issn.1009-2137.2017.05.022	2017	[Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].	IRF4
26119939	10.1038/onc.2015.245	2016	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.	IRF4
26414904	10.1002/cncy.21626	2016	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.	IRF4
26416032	10.1007/s00428-015-1855-z	2016	Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.	IRF4
26526666	10.1007/s00431-015-2660-z	2016	Hodgkin lymphoma as a novel presentation of familial DICER1 syndrome.	IRF4
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	IRF4
26762526	10.1007/s00428-015-1902-9	2016	Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of ""germinotropic"" lymphoproliferative disorder.	IRF4
26851186	10.1158/1078-0432.CCR-15-1784	2016	STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.	IRF4
26869285	10.1002/cam4.650	2016	Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.	IRF4
26878872	10.18632/aging.100898	2016	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.	IRF4
26910115	10.18632/oncotarget.7495	2016	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.	IRF4
26932576	10.1038/leu.2016.27	2016	PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.	IRF4
27102442	10.18632/oncotarget.8836	2016	JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms.	IRF4
27169444	10.11406/rinketsu.57.417	2016	[Genetic landscape of adult T-cell leukemia/lymphoma].	IRF4
27408374	10.1007/s12288-015-0549-7	2016	Plasmablastic Lymphoma of Small Intestine: A Rare Case Report with Review of Literature.	IRF4
27419920	10.1002/ajh.24485	2016	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.	IRF4
27664237	10.1101/gad.283762.116	2016	Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia.	IRF4
27799566	10.1073/pnas.1610970113	2016	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.	IRF4
25131361	10.1111/his.12529	2015	Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features.	IRF4
25252151	10.3109/08880018.2014.954071	2015	Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus.	IRF4
25359993	10.1182/blood-2014-08-594507	2015	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.	IRF4
25687653	10.1038/leu.2015.43	2015	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.	IRF4
25817328	10.1093/neuonc/nov046	2015	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.	IRF4
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	IRF4
25833963	10.1182/blood-2014-05-578575	2015	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-ÎºB positive feedback loop in peripheral T-cell lymphoma.	IRF4
26034867	10.1097/PAS.0000000000000445	2015	Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.	IRF4
26056791	10.1097/MPH.0000000000000368	2015	Cytotoxic Molecule-positive Epstein-Barr Virus-associated Peripheral T-cell Lymphoma in a 20-Month-old Child: A Case Report and Review of the Literature.	IRF4
26173642	10.1002/gcc.22268	2015	The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.	IRF4
26284337	10.1038/bjc.2015.274	2015	Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.	IRF4
26289642	10.1182/blood-2015-02-626176	2015	The forkhead transcription factor FOXP1 represses human plasma cell differentiation.	IRF4
26299509	10.1016/j.humpath.2015.06.020	2015	Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus-copositive lymphoproliferations.	IRF4
26307535	10.1182/blood-2015-06-649905	2015	Cell of origin of transformed follicular lymphoma.	IRF4
26360498	10.1038/modpathol.2015.99	2015	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.	IRF4
26376702	10.1136/bcr-2015-211960	2015	Rare presentation of orbital plasmablastic lymphoma with oral cavity involvement in an HIV-negative patient.	IRF4
26437031	10.1038/ng.3415	2015	Integrated molecular analysis of adult T cell leukemia/lymphoma.	IRF4
26604798	10.2147/OTT.S90057	2015	Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.	IRF4
26617862		2015	MUM-1 expression differentiates AITL with HRS-like cells from cHL.	IRF4
26960478	10.4103/0019-509X.178437	2015	Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India.	IRF4
23647062	10.3109/10428194.2013.800196	2014	Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.	IRF4
23989669	10.1007/s00277-013-1889-8	2014	Refractory IGÎº/IRF4-positive DLBCL with CDKN2A/2B deletion.	IRF4
24030746	10.1038/modpathol.2013.156	2014	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.	IRF4
24153013	10.1038/leu.2013.308	2014	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.	IRF4
24265352	10.1093/annonc/mdt385	2014	Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.	IRF4
24335298	10.1128/JVI.02106-13	2014	Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.	IRF4
24344258	10.1073/pnas.1321704111	2014	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	IRF4
24604141	10.1007/s00428-014-1560-3	2014	Peripheral T-cell lymphoma with t(6;14)(p25;q11.2) translocation presenting with massive splenomegaly.	IRF4
24704296	10.1016/j.canlet.2014.03.030	2014	The NF-ÎºB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.	IRF4
24721791	10.1038/leu.2014.106	2014	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.	IRF4
24805854	10.1097/PAS.0000000000000217	2014	Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.	IRF4
24805861	10.1097/PAS.0000000000000225	2014	Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.	IRF4
24875472	10.1093/nar/gku451	2014	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.	IRF4
24928034	10.1016/j.virol.2014.04.020	2014	Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells.	IRF4
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	IRF4
25149549	10.1016/j.humpath.2014.06.019	2014	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.	IRF4
25207815	10.1371/journal.pone.0106788	2014	Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.	IRF4
25232062	10.1182/blood-2014-07-590570	2014	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.	IRF4
25236575	10.1016/j.yexmp.2014.09.014	2014	Analysis of biological and technical variability in gene expression assays from formalin-fixed paraffin-embedded classical Hodgkin lymphomas.	IRF4
25265348		2014	Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and transcription factors expression profile.	IRF4
25282160	10.1038/ni.3008	2014	Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation.	IRF4
25439346	10.1016/j.humpath.2014.09.002	2014	Diffuse large B-cell lymphoma occurring in an ovarian cystic teratoma: expanding the spectrum of large B-cell lymphoma associated with chronic inflammation.	IRF4
22966948	10.3109/10428194.2012.728597	2013	Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.	IRF4
23073988	10.1002/gcc.22014	2013	High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.	IRF4
23108024	10.1097/PAS.0b013e31826b9b57	2013	Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma.	IRF4
23252516	10.1111/bjh.12172	2013	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	IRF4
23255160	10.1007/s12185-012-1244-1	2013	Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.	IRF4
23269792	10.1128/JVI.03003-12	2013	Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.	IRF4
23300175	10.3324/haematol.2012.076851	2013	A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement.	IRF4
23332472	10.1016/j.leukres.2012.12.001	2013	The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.	IRF4
23348205	10.1097/PAS.0b013e31826cebad	2013	Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.	IRF4
23355206	10.1309/AJCP0YGM8BLFYHJY	2013	Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.	IRF4
23445872	10.3324/haematol.2012.073916	2013	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.	IRF4
23449597	10.3324/haematol.2013.084582	2013	Reply to ""A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm"" and to ""A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement"" dendritic cell leukemia.	IRF4
23455380	10.1093/carcin/bgt082	2013	Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese population.	IRF4
23599146	10.1038/modpathol.2013.50	2013	Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients.	IRF4
23648461	10.1097/PAS.0b013e318282d01e	2013	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.	IRF4
23726928	10.1016/j.prp.2013.04.014	2013	Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.	IRF4
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	IRF4
23783577	10.1158/0008-5472.CAN-12-3546	2013	Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.	IRF4
23804715	10.4049/jimmunol.1202514	2013	Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.	IRF4
23977280	10.1371/journal.pone.0072326	2013	Implication of IRF4 aberrant gene expression in the acute leukemias of childhood.	IRF4
23980171	10.1073/pnas.1309378110	2013	The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells.	IRF4
23995111	10.3960/jslrt.53.141	2013	Double-hit lymphoma demonstrating t(6;14;18)(p25;q32;q21), suggesting two independent dual-hit translocations, MYC/BCL-2 and IRF4/BCL-2.	IRF4
24121164	10.1038/bcj.2013.49	2013	Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma.	IRF4
21756027	10.3109/10428194.2011.605190	2012	The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment.	IRF4
22024108	10.1016/j.exphem.2011.10.004	2012	Bortezomib-resistant nuclear factor ÎºB expression in stem-like cells in mantle cell lymphoma.	IRF4
22102710	10.3324/haematol.2011.048132	2012	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.	IRF4
22213394	10.1002/cncr.27396	2012	Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.	IRF4
22238326	10.1182/blood-2011-10-388470	2012	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.	IRF4
22251943	10.1097/PAS.0b013e31823ea106	2012	Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas.	IRF4
22308355	10.1073/pnas.1113019109	2012	Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis.	IRF4
22314189	10.1097/PAS.0b013e31824433d8	2012	Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and Î±Î², Î³Î´, and Î±Î²/Î³Î´ T-cell origin: a comprehensive clinicopathologic and phenotypic study.	IRF4
22372911	10.5858/arpa.2010-0747-RS	2012	Intravascular large B-cell lymphoma.	IRF4
22388754	10.1038/modpathol.2012.38	2012	Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.	IRF4
22409820	10.1016/j.beha.2012.01.004	2012	New biomarkers in T-cell lymphomas.	IRF4
22422878	10.4049/jimmunol.1103302	2012	p110Î´ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.	IRF4
22442255	10.1074/mcp.M111.015362	2012	Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles.	IRF4
22552227	10.1073/pnas.1205834109	2012	Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation.	IRF4
22627742	10.1038/modpathol.2012.70	2012	Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features.	IRF4
22698399	10.1016/j.ccr.2012.05.024	2012	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.	IRF4
22700993	10.1093/annonc/mds150	2012	Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.	IRF4
22762030		2012	Subtle bone marrow involvement by large B-cell lymphoma with pronormoblast-like morphology and prominent but not exclusive sinusoidal distribution.	IRF4
22955914	10.1182/blood-2012-05-428896	2012	Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.	IRF4
22994707	10.7314/apjcp.2012.13.7.3037	2012	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.	IRF4
23009111	10.1111/j.1600-0463.2012.02915.x	2012	Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFÎºB pathway.	IRF4
23149704		2012	Indolent cutaneous B-cell lymphoma: diagnosis and treatment 2012.	IRF4
20956803	10.1182/blood-2010-02-269514	2011	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.	IRF4
21114485	10.1111/j.1365-2141.2010.08497.x	2011	IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.	IRF4
21131593	10.1182/blood-2010-08-303123	2011	A role for Blimp1 in the transcriptional network controlling natural killer cell maturation.	IRF4
21169992	10.1038/modpathol.2010.225	2011	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.	IRF4
21393330	10.3324/haematol.2010.031138	2011	Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.	IRF4
21424034		2011	B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.	IRF4
21441466	10.1182/blood-2010-12-322362	2011	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.	IRF4
21487109	10.1182/blood-2011-01-330795	2011	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.	IRF4
21569705		2011	[Correlation between the expressions of CARMA1 gene and MUM1 and its significance in diffuse large B cell lymphoma].	IRF4
21623692	10.3109/10428194.2011.573032	2011	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.	IRF4
21659362	10.3324/haematol.2011.042531	2011	Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.	IRF4
21680528	10.1128/JVI.00570-11	2011	Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.	IRF4
21761432	10.1002/ajh.22078	2011	EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.	IRF4
21867533	10.1186/1746-1596-6-79	2011	Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.	IRF4
21890374	10.1016/j.cyto.2011.08.014	2011	Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel.	IRF4
21915363		2011	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.	IRF4
21934230	10.4103/0377-4929.85104	2011	Primary cardiac diffuse large B-cell lymphoma with activated B-cell-like phenotype.	IRF4
21997689	10.1097/PAS.0b013e31822bd8a8	2011	Clinicopathologic and genetic characterization of follicular lymphomas presenting in the ovary reveals 2 distinct subgroups.	IRF4
22041376	10.2169/internalmedicine.50.5815	2011	Double-hit lymphoma with t(8;14)(q24;q32) and t(12;14)(q24;q32) chromosomal translocations.	IRF4
22158496	10.1700/989.10724	2011	Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.	IRF4
22169641		2011	[Significance of MUM-1/IRF4 protein expression in follicular lymphoma].	IRF4
18815567	10.1097/PAI.0b013e31817fa43c	2010	Translocations involving MUM1 are rare in diffuse large B-cell lymphoma.	IRF4
19710685	10.1038/jid.2009.270	2010	Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.	IRF4
19804451	10.1111/j.1365-2141.2009.07946.x	2010	IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.	IRF4
19812605	10.1038/jid.2009.314	2010	IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.	IRF4
19821826	10.1111/j.1365-2141.2009.07945.x	2010	IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.	IRF4
19897031	10.1016/j.bbadis.2009.10.015	2010	An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males.	IRF4
19925052	10.3109/10428190903370338	2010	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.	IRF4
20054341	10.1038/jid.2009.418	2010	IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type.	IRF4
20080768	10.1073/pnas.0912920107	2010	IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.	IRF4
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	IRF4
20182347	10.1097/PAI.0b013e3181cf1126	2010	MUM1/IRF4: A Review.	IRF4
20185248	10.1016/j.prp.2010.01.003	2010	Mediastinal lymphomas: primary mediastinal (thymic) large B-cell lymphoma versus classical Hodgkin lymphoma, histopathologic dilemma solved?	IRF4
20408839	10.1111/j.1365-2141.2010.08199.x	2010	A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.	IRF4
20736456	10.1182/blood-2010-03-276766	2010	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.	IRF4
18987657	10.1038/leu.2008.320	2009	Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.	IRF4
19047678	10.1182/blood-2008-10-184077	2009	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.	IRF4
19103865	10.1136/jcp.2008.059519	2009	p63 protein expression in high risk diffuse large B-cell lymphoma.	IRF4
19144381	10.1016/j.humpath.2008.07.021	2009	Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.	IRF4
19287457	10.1038/modpathol.2009.36	2009	HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma.	IRF4
19377508	10.1038/onc.2009.74	2009	Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.	IRF4
19390683	10.1371/journal.pone.0005360	2009	Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk.	IRF4
19396635	10.1007/s10552-009-9348-5	2009	Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma.	IRF4
19448593	10.1038/modpathol.2009.73	2009	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.	IRF4
19484731	10.1002/ajh.21434	2009	Differentiating germinal center-derived lymphomas through their cellular microenvironment.	IRF4
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	IRF4
19656156	10.1111/j.1349-7006.2009.01268.x	2009	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.	IRF4
19669219	10.1007/s12308-009-0021-4	2009	Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.	IRF4
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	IRF4
19769942	10.1016/j.bbrc.2009.09.059	2009	Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation.	IRF4
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	IRF4
19786664	10.1200/JCO.2009.22.7058	2009	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.	IRF4
19787248	10.3892/ijo_00000409	2009	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.	IRF4
19880780	10.3324/haematol.2009.008862	2009	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.	IRF4
19917431	10.1016/j.annder.2009.02.005	2009	[Cutaneous large B-cell leg-type lymphoma occurring on a leg burn].	IRF4
20003543	10.1186/1472-6890-9-11	2009	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda.	IRF4
20309427	10.1007/s12308-009-0044-x	2009	A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score.	IRF4
18231914	10.1080/10428190701760037	2008	MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia.	IRF4
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	IRF4
18324968	10.1111/j.1365-2141.2008.07011.x	2008	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis.	IRF4
18436278	10.1016/j.humpath.2007.10.025	2008	B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray.	IRF4
18580679	10.1097/PAS.0b013e318166f46a	2008	Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.	IRF4
18925696	10.3325/cmj.2008.5.625	2008	Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.	IRF4
18983461	10.1111/j.1365-2559.2008.03144.x	2008	Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).	IRF4
16954503	10.1182/blood-2006-04-014977	2007	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.	IRF4
17038524	10.1182/blood-2006-08-039024	2007	The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.	IRF4
17098231	10.1016/j.yexcr.2006.10.015	2007	B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.	IRF4
17296566	10.3324/haematol.10724	2007	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms.	IRF4
17296585	10.3324/haematol.10682	2007	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.	IRF4
17356384	10.1097/01.jnen.0000248553.45456.96	2007	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	IRF4
17614857	10.1111/j.1600-0463.2007.apm_631.x	2007	Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern.	IRF4
17635238	10.1111/j.1600-0609.2007.00892.x	2007	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.	IRF4
17651861	10.1016/j.ejcb.2007.05.006	2007	IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.	IRF4
17768115	10.3324/haematol.11523	2007	A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.	IRF4
17785200	10.1016/j.ccr.2007.08.012	2007	The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.	IRF4
17785208	10.1016/j.ccr.2007.08.011	2007	A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.	IRF4
18039900	10.1354/vp.44-6-875	2007	Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.	IRF4
19455257		2007	Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival.	IRF4
16323006	10.1007/s00428-005-0122-0	2006	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.	IRF4
16396779	10.1080/10428190500144680	2006	Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis.	IRF4
16426914	10.1016/j.humpath.2005.09.029	2006	The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.	IRF4
16585013		2006	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.	IRF4
16778825	10.1038/modpathol.3800650	2006	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma.	IRF4
16943530	10.1200/JCO.2006.05.5897	2006	Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.	IRF4
17056545	10.4049/jimmunol.177.9.6165	2006	Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential.	IRF4
17082608	10.4049/jimmunol.177.10.6930	2006	Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance.	IRF4
17149956	10.5858/2006-130-1819-ICODNT	2006	Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.	IRF4
15308563	10.1182/blood-2004-04-1594	2005	Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.	IRF4
15510210	10.1038/sj.leu.2403543	2005	Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in ""unmutated"" B-CLL.	IRF4
15578069	10.1038/modpathol.3800355	2005	Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.	IRF4
15611260	10.4049/jimmunol.174.1.367	2005	Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.	IRF4
15677569	10.1182/blood-2004-08-3112	2005	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.	IRF4
15701085	10.1111/j.0303-6987.2005.00298.x	2005	Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study.	IRF4
15710572		2005	Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup.	IRF4
15722318	10.1136/bjo.2004.047092	2005	Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.	IRF4
15735858	10.1177/106689690501300110	2005	Follicular colonization of nodal marginal-zone B-cell lymphoma resembling follicular lymphoma: report of 6 cases.	IRF4
15749666		2005	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.	IRF4
15832089	10.1097/01.pas.0000157937.01624.1d	2005	HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man.	IRF4
15905193	10.1182/blood-2004-12-4631	2005	AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping.	IRF4
15959530	10.1038/sj.leu.2403833	2005	Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.	IRF4
16249468	10.1167/iovs.05-0318	2005	Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.	IRF4
16342298	10.1002/hon.764	2005	Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.	IRF4
14685876	10.1007/s00417-003-0831-5	2004	Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases.	IRF4
15087665	10.1097/00000478-200404000-00005	2004	Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.	IRF4
15220833	10.1016/s0242-6498(04)93937-5	2004	[Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis].	IRF4
12507907	10.1016/s0002-9440(10)63815-1	2003	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.	IRF4
15202521	10.1080/10428190310001623810	2003	Pathobiology of primary mediastinal B-cell lymphoma.	IRF4
11781220	10.1182/blood.v99.2.409	2002	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.	IRF4
11846984	10.1089/107999002753452746	2002	IRF-4 activities in HTLV-I-induced T cell leukemogenesis.	IRF4
11972519	10.1046/j.1365-2141.2002.03456.x	2002	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease.	IRF4
12079517	10.1111/j.1349-7006.2002.tb01307.x	2002	MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).	IRF4
12200383	10.1182/blood-2002-01-0008	2002	A molecular compendium of genes expressed in multiple myeloma.	IRF4
12379751	10.1097/01.MP.0000027624.08159.19	2002	CD5+ T-cell/histiocyte-rich large B-cell lymphoma.	IRF4
11157493	10.1182/blood.v97.3.744	2001	Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.	IRF4
11299818		2001	Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.	IRF4
11455001	10.1038/modpathol.3880373	2001	Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry.	IRF4
11520558	10.1016/s0165-4608(01)00436-8	2001	Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma.	IRF4
11749693	10.1111/j.1349-7006.2001.tb02151.x	2001	Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia.	IRF4
10706878		2000	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.	IRF4
10720141	10.1038/sj.leu.2401696	2000	MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies.	IRF4
11013272	10.1200/JCO.2000.18.19.3331	2000	Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.	IRF4
11067898	10.4049/jimmunol.165.10.5462	2000	Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo.	IRF4
11091208	10.1046/j.1365-2141.2000.02329.x	2000	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis.	IRF4
